flunarizine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics/cerebral (or peripheral) vasodilators 1200 52468-60-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flunarizine
  • sibelium
  • flunarizine dihydrochloride
  • flunarizine hydrochloride
  • flunarizine HCl
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
  • Molecular weight: 404.51
  • Formula: C26H26F2N2
  • CLOGP: 6.34
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -5.38
  • ROTB: 6

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07CA03 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
ANTIVERTIGO PREPARATIONS
Antivertigo preparations
MeSH PA D000927 Anticonvulsants
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.42 Basic
pKa2 3.42 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent T-type calcium channel subunit alpha-1G Ion channel BLOCKER Kd 6.28 CHEMBL SCIENTIFIC LITERATURE
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel BLOCKER Kd 5.44 CHEMBL SCIENTIFIC LITERATURE
Voltage-dependent T-type calcium channel subunit alpha-1I Ion channel BLOCKER Kd 6.08 CHEMBL SCIENTIFIC LITERATURE
Alpha-2A adrenergic receptor GPCR Ki 6.66 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 8 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 6.30 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.58 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.88 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.61 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.94 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.16 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.45 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.06 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.48 DRUG MATRIX
Histamine H1 receptor GPCR Ki 7.74 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.15 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.50 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.10 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.10 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.49 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.33 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.53 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.36 DRUG MATRIX
Sodium channel protein type 1 subunit alpha Ion channel IC50 6.20 WOMBAT-PK
Kappa-type opioid receptor GPCR IC50 5.02 CHEMBL
Delta-type opioid receptor GPCR IC50 5.44 CHEMBL
Mu-type opioid receptor GPCR IC50 5.62 CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 5.78 CHEMBL
CAAX prenyl protease 2 Enzyme AC50 4.15 CHEMBL
Cannabinoid receptor 1 GPCR Ki 5.62 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.71 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 6.93 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.22 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 7.42 DRUG MATRIX
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel Ki 7.28 CHEMBL
D(2) dopamine receptor GPCR IC50 6.64 CHEMBL
Sodium channel protein type 2 subunit alpha Ion channel IC50 6.31 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.37 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 5.96 CHEMBL
CAAX prenyl protease 2 Unclassified AC50 5.46 CHEMBL

External reference:

IDSource
D005444 MESH_DESCRIPTOR_UI
N0000167125 NUI
C0016295 UMLSCUI
D01303 KEGG_DRUG
4459 RXNORM
003847 NDDF
C11102TO53 UNII
30484-77-6 SECONDARY_CAS_RN
CHEMBL30008 ChEMBL_ID
CHEMBL552659 ChEMBL_ID
CHEMBL539027 ChEMBL_ID
2686 INN_ID
DB04841 DRUGBANK_ID
CHEBI:135652 CHEBI
941361 PUBCHEM_CID

Pharmaceutical products:

None